{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T04:23:59Z","timestamp":1745987039636,"version":"3.40.4"},"reference-count":61,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":6672,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1994,12]]},"abstract":"<jats:p>Eight hypertensive patients with noninsulin dependent diabetes mellitus (NIDDM) were administered the experimental drug pyrazinoylguanidine (PZG) either alone or in combination with calcium\u2010channel or \u03b2\u2010blockers. This treatment appeared to \u201cdownregulate\u201d the glucose fatty acid cycle and reduced both systolic and diastolic blood pressures and mean body weight. Patients served as their own controls in this dose\u2010escalation study, which included placebo treatment (baseline) 3 weeks, 300 mg PZG for 3 weeks and 600 mg for 3 weeks. PZG reduced increased serum concentrations of free fatty acids (FFA), glucose, and triglycerides (TG). TG concentrations correlated inversely with serum HDL\u2010cholesterol concentrations. The beta\u2010blockers used by several patients increased their FFA, glucose, insulin and TG concentrations, as well as blunting their response to PZG. The calcium\u2010channel blockers exerted these effects to a much lesser extent. PZG reduced or abolished glycosuria, related to PZG's capacity to decrease hyperglycemia. Withdrawal of PZG restored glycosuria, as blood sugar increased. PZG was well tolerated. No patient reported any adverse effect or missed a weekly clinic visit (12 weeks). PZG deserves further study as supplementary and\/or replacement therapy in NIDDM patients who are hypertensive and hyperlipidemic.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1994.tb04737.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T19:58:03Z","timestamp":1362772683000},"page":"1234-1245","source":"Crossref","is-referenced-by-count":3,"title":["Pyrazinoylguanidine Downregulates the Glucose Fatty\u2010Acid Cycle in Hypertensive, Hyperinsulinemic Diabetic Patients"],"prefix":"10.1002","volume":"34","author":[{"given":"Elliot S.","family":"Vesell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles E.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa DeAngelo","family":"Seaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Thomas","family":"Passananti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence M.","family":"Demers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Karl H.","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/4.3.283"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90057-5"},{"key":"e_1_2_1_4_2","first-page":"75","article-title":"Contribution of estimated insulin resistance and glucose intolerance to essential hypertension","volume":"735","author":"Eriksson KF","year":"1991","journal-title":"J Intern Med"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199103000-00004"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(63)91500-9"},{"key":"e_1_2_1_7_2","first-page":"78","article-title":"Resistance to insulin\u2010stimulated glucose uptake and hyperinsulinemia; role in non\u2010insulin\u2010dependent diabetes, high blood pressure, dyslipidemia and coronary heart disease","volume":"17","author":"Reaven GM","year":"1991","journal-title":"Diabetes Metab"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00405111"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304293281702"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(86)90296-6"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-98-5-855"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1978.03290150053024"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.17.4.565"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199212071-00001"},{"key":"e_1_2_1_15_2","first-page":"1","article-title":"Hypertension as a metabolic disorder\u2014an overview","volume":"735","author":"Smith U","year":"1991","journal-title":"J Intern Med"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI105886"},{"key":"e_1_2_1_17_2","first-page":"51","article-title":"The association of essential hypertension and diabetes","volume":"15","author":"Ferrannini E","year":"1989","journal-title":"Comp Ther"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/5.6.345"},{"key":"e_1_2_1_19_2","first-page":"4","article-title":"Diabetes mellitus in the elderly. A modifyable risk factor for cardiovascular disease","volume":"12","author":"Simon NR","year":"1993","journal-title":"Pract Diabetol"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2337\/diab.36.4.523","article-title":"Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20\u201374 years","volume":"36","author":"Harris MI","year":"1987","journal-title":"Diabetes"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)36134-2"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/6.4S.123S"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.me.44.020193.001005"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1993.tb01958.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.84"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1993.tb04703.x"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127009203201212"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000138991"},{"key":"e_1_2_1_29_2","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/archinte.1987.00370060031006","article-title":"Abnormalities of carbohydrate and lipid metabolism in patients with hypertension","volume":"147","author":"Fuh MMT","year":"1987","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI105666"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.37.12.1595"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.30.3.219"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(80)90023-2"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.14.040174.002053"},{"key":"e_1_2_1_35_2","first-page":"151","article-title":"Consequences of inhibition of normal and excessive lipid metabolism","volume":"3","author":"Carlson LA","year":"1967","journal-title":"Progr Biochem Pharmacol"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1962.tb07203.x"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111133"},{"key":"e_1_2_1_38_2","first-page":"635","article-title":"Regulation of adipose\u2010tissue lipolysis by phosphorylation of hormone\u2010sensitive lipase","volume":"5","author":"Belfrage P","year":"1981","journal-title":"Int J Obes"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-115-3-1151"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2760(84)90017-1"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/scientificamerican0192-86"},{"key":"e_1_2_1_42_2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1096\/fasebj.4.2.2153593","article-title":"Various proteins modulate the kinase activity of the insulin receptor","volume":"4","author":"Yonezawa K","year":"1990","journal-title":"FASEB J"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.7.11.8370473"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.15.5473"},{"key":"e_1_2_1_45_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0022-3565(25)31343-1","article-title":"The mechanism of chlorothiazide\u2010induced carbohydrate intolerance","volume":"206","author":"Hoskins B","year":"1978","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmr.5610030209"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6679.998"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198911093211907"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.79.1.8"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.24.6.247"},{"key":"e_1_2_1_51_2","first-page":"235","article-title":"Effects of diltiazem hydrochloride on glucose tolerance in persons at risk for diabetes mellitus","volume":"7","author":"Jones BJ","year":"1988","journal-title":"Clin Pharmacol"},{"key":"e_1_2_1_52_2","first-page":"1075","article-title":"Effects of nifedipine treatment on carbohydrate and lipoprotein metabolism","volume":"33","author":"Vessby B","year":"1983","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-110-2-171_2"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-27-10-1441"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197600111-00027"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6157.159"},{"key":"e_1_2_1_57_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.0954-6820.1983.tb01616.x","article-title":"\u03b2\u2010adrenergic blockade and diabetes mellitus","volume":"672","author":"Ostman J","year":"1983","journal-title":"Acta Med Scand"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002808501900401"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1014697"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198801143180204"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1987.03390010037024"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1993.tb04707.x"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1994.tb04737.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1994.tb04737.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T23:39:27Z","timestamp":1745969967000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1994.tb04737.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,12]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[1994,12]]}},"alternative-id":["10.1002\/j.1552-4604.1994.tb04737.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1994.tb04737.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"type":"print","value":"0091-2700"},{"type":"electronic","value":"1552-4604"}],"subject":[],"published":{"date-parts":[[1994,12]]}}}